Worth reading
55In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
48000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of stock acquisition rights with an exercise price adjustment clause
発行・処分する株式数
48,000 new shares (25 May 2026)
発行済株式総数
Exercise ratio under the exercise restriction: 0.25% (48,000 shares delivered / 19,196,700 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price on 25 May 2026: ¥407.70. On other dates, ¥389.7 or ¥407.70. Details of the adjustment provisions: Not disclosed
Number of Stock Acquisition Rights
480 rights exercised in May, representing 0.62% of the total number issued; 76,983 rights remained unexercised at the end of the preceding month, and 76,503 at month-end
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financing
docirbrutinib (AS-1763) development acceleration stock acquisition rights issued on 17 February 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | 48,000 new shares (25 May 2026) |
| Dilution Rate | Exercise ratio under the exercise restriction: 0.25% (48,000 shares delivered / 19,196,700 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 19,697,501 shares (as of the end of the month preceding the relevant month, including 11,136 treasury shares) → Not disclosed |
| Exercise price | Exercise price on 25 May 2026: ¥407.70. On other dates, ¥389.7 or ¥407.70. Details of the adjustment provisions: Not disclosed |
| Number of Stock Acquisition Rights | 480 rights exercised in May, representing 0.62% of the total number issued; 76,983 rights remained unexercised at the end of the preceding month, and 76,503 at month-end |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc. |
| Most recent equity financing | docirbrutinib (AS-1763) development acceleration stock acquisition rights issued on 17 February 2026 |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is reporting the monthly exercise status in May 2026 of the stock acquisition rights issued on 17 February 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.